Screening for Oculocerebral Lymphoma with the Phenotype of NK Cells in Patients with Uveitis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-06-01

Study Completion Date

2025-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Uveitis is an inflammation of the uvea, an ocular tunic comprising the iris, ciliary body and choroid. This inflammation can also involve other tissues such as the retina, the optic nerve and the aqueous humor. These diseases can result in significant vision loss and account for 10% of all blindness in developed countries, and up to 25% in developing countries. The main difficulty in this pathology is to make the etiological diagnosis, which then allows a specific treatment of the disease. The main etiologie are inflammatory or infectious (sarcoidosis, tuberculosis) but other cancerous etiologies are possible and are of more complicated diagnosis.

Vitreoretinal lymphoma is a subtype of central nervous system lymphoma, which is generally associated with a poor prognosis. It is a diffuse non-Hodgkin's lymphoma, with large B cells. It can be primary ocular (Primary Intra-Ocular Lymphoma - LIOP), without brain involvement, but can also be secondary to central nervous system involvement, which explains the poor prognosis of the disease. Approximately 50-90% of LIOP develop brain involvement within 1-2 years of diagnosis, which encourages early diagnosis to avoid brain involvement as much as possible.

The main obstacle to rapid diagnosis is the difficulty of identifying LIOP. Indeed, the clinical symptoms of this rare disease are often identical to classical uveitis, and the diagnostic means to detect it are invasive and require a trained ophthalmologist and hematologist team. LIOP diagnostic tests are often delay in the management of uveitis and lead to diagnostic erraticity that can last between 4 to 40 months.

The INSERM U1183 unit is developing a diagnostic technology for lymphomas based on the analysis of blood NK cells and their phenotypes including those acquired by trogocytosis (WO/2016/005548).

A rapid, simple, minimally invasive LIOP test using this technology could therefore be propose to all patients presenting with uveitis and whose clinical criteria could match those of LIOP.

The research hypothesis is : Could the diagnostic wandering of patients with primary intraocular lymphoma be reduced by a rapid blood test for NK cell phenotype of patients with uveitis? Following a simple blood test, a rapid LIOP test, using this diagnostic technology, could therefore be proposed to all patients with uveitis and clinical criteria (age, intermediate and posterior location of the uveitis) corresponding to those of LIOP.

The primary objective of this study is to compare the phenotype of circulating NK cells of patient with untreated intraocular lymphoma versus the phenotype of patient with non-cancerous uveitis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Risk Factors for Therapeutic Failure in Chronic Non-Infectious Uveitis After First-Line Immunosuppressive Therapy

NCT06821971

Uveitis

ACTIVE_NOT_RECRUITING

Analysis of Eye Tissue

NCT00001224

Eye Disease Inflammation Uveitis

COMPLETED

Biomarkers in Ocular Inflammation and Uveitis

NCT04690829

Uveitis Ocular Inflammation

COMPLETED

The Vitreous Proteome and Inflammatory Mediators in Ocular Inflammatory Disease

NCT00331331

Uveitis Vasculitis Ocular Inflammatory Disease

COMPLETED

Evaluation and Treatment of Patients With Inflammatory Eye Diseases

NCT00006188

Choroiditis Iridocyclitis Iritis +1 more

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Uveitis Lymphoma NK-Cell Lymphoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Prospective Case Control Study

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Negative control

uveitis patients with a diagnosis other than ocular diagnosis other than ocular lymphoma and without cerebral lymphoma (15 patients),

Group Type ACTIVE_COMPARATOR

Blood sample

Intervention Type BIOLOGICAL

Blood sample will be taken at D0: 63 ml (7 tubes of 9 ml),

Primary ocular Lymphoma without brain involvementand never treated

patients with primary ocular lymphoma without brain involvement and never treated (5 patients),

Group Type ACTIVE_COMPARATOR

Blood sample

Intervention Type BIOLOGICAL

Blood sample will be taken at D0: 63 ml (7 tubes of 9 ml),

Primary ocular Lymphoma without brain involvement and treated

patients with primary ocular lymphoma without brain involvement, treated and considered in remission (5 patients),

Group Type ACTIVE_COMPARATOR

No interventions assigned to this group

Primary ocular Lymphoma without brain involvement in relapse

patients with primary ocular lymphoma without brain involvement, considered in relapse (5 patients),

Group Type ACTIVE_COMPARATOR

Blood sample

Intervention Type BIOLOGICAL

Blood sample will be taken at D0: 63 ml (7 tubes of 9 ml),

Positive control

patients with cerebral lymphoma with or without ocular involvement and without uveitis (15 patients).

Group Type ACTIVE_COMPARATOR

Blood sample

Intervention Type BIOLOGICAL

Blood sample will be taken at D0: 63 ml (7 tubes of 9 ml),

Patients without brain involvement and without uveitis

Patients presenting for cataract follow-up (pre- or post-operative), glaucoma, retinal detachment or epiretinal membrane, with no brain damage or uveitis (15 patients).

Group Type ACTIVE_COMPARATOR

Blood sample

Intervention Type BIOLOGICAL

Blood sample will be taken at D0: 63 ml (7 tubes of 9 ml),

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Blood sample

Blood sample will be taken at D0: 63 ml (7 tubes of 9 ml),

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

GENERAL CRITERIA

* Male or female over 18 years of age,
* Free, informed, written consent signed by the patient and the investigator (at the latest on the day of inclusion) and before any examination required by the research,
* Patient affiliated to the social security system or beneficiary of such a system,
* Maximum volume of sampling (care + research) per 30-day period to be adapted according to the patient's weight (Order of April 12, 2018 establishing the list of research mentioned in 2° of Article L. 1121-1).

SPECIFIC CRITERIA

\- Patient affected in one or both eyes: of uveitis with another diagnosis than ocular lymphoma and without cerebral lymphoma (Group 1), or primary ocular lymphoma without brain involvement and never treated (Group 2), or primary ocular lymphoma without brain involvement, treated and considered in remission (IL10 HA level \< 10) (Group 3), or primary ocular lymphoma without brain involvement, and considered in relapse (IL10 HA level \> 30) (Group 4), or cerebral lymphoma with or without ocular involvement and without uveitis (Group 5), or cataract (pre- and post-op), glaucoma, retinal detachment or epiretinal retinal detachment or epiretinal membrane, but no brain damage or uveitis (group 6).

Exclusion Criteria

* -GENERAL CRITERIA
* Patient participating in an ongoing clinical trial at the time of the inclusion visit,
* Pregnant women, women in labor or nursing mothers,
* Persons deprived of liberty by a judicial or administrative decision,
* Persons under psychiatric care,
* Persons admitted to a health or social institution for purposes other than research,
* Persons of full age who are subject to a legal protection measure (guardianship, curatorship).

SPECIFIC CRITERIA

* Patient for whom the diagnosis of ocular or cerebral lymphoma is uncertain,
* Patient with another systemic cancer that is evolving or in remission \< 2 years.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No